Bloodwise’s Trials Acceleration Programme (TAP) aims to boost the number and speed of hematological oncology studies in the UK. Here, Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK, summarizes the latest results of the TAP CLARITY study (ISCRTN13751862), which assessed the use of venetoclax in combination with ibrutinib in relapsed/refractory chronic lymphocytic leukemia (CLL). Prof. Schuh emphasizes the exciting objective response and MRD rates at 8 months, and discusses the plans for continuation to a Phase III trial. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
The TAP CLARITY study: latest results and future plans
